Answered step by step
Verified Expert Solution
Link Copied!

Question

1 Approved Answer

AUGUST 17, 20179:35 AMUPDATED 3 YEARS AGO Mylan, U.S. finalize $465 million EpiPen settlement ByNate Raymond 4 MIN READ BOSTON (Reuters) - Mylan NVMYL.Ohas finalized

AUGUST 17, 20179:35 AMUPDATED 3 YEARS AGO

Mylan, U.S. finalize $465 million EpiPen settlement

ByNate Raymond

4 MIN READ

BOSTON (Reuters) - Mylan NVMYL.Ohas finalized a $465 million settlement resolving U.S. Justice Department claims it overcharged the government for its EpiPen emergency allergy treatment, which became the center of a firestorm over price increases.

EpiPen auto-injection epinephrine pens manufactured by Mylan NV pharmaceutical company for use by severe allergy sufferers are seen in Washington, U.S. August 24, 2016. REUTERS/Jim Bourg/File Photo

The U.S. Attorney's Office in Massachusetts on Thursday announced the accord, which was soon after criticized by some congressional members as being too easy on the drugmaker. It came 10 months after Mylan said it had reached a deal.

The settlement resolved claims that Mylan avoided higher rebates to state Medicaid programs by misclassifying EpiPen as a generic product, even though it was marketed and priced as a brand-name product.

"Taxpayers rightly expect companies like Mylan that receive payments from taxpayer-funded programs to scrupulously follow the rules," Acting U.S. Attorney William Weinreb said in a statement.

Under the deal, Mylan did not admit wrongdoing. It will reclassify EpiPen and pay the rebate applicable to its new classification as of April 1, 2017.

"Bringing closure to this matter is the right course of action for Mylan and our stakeholders to allow us to move forward," Mylan Chief Executive Heather Bresch said in a statement.

The deal followed a False Claims Act whistleblower lawsuit filed by French rival Sanofi SASASY.PAin 2016, two years after it first raised the matter with authorities, Weinreb's office said.

Sanofi, which formerly marketed a rival product called Auvi-Q, will receive nearly $38.8 million as a reward from the government.

Sanofi in a statement called pursuing the matter "the right thing to do." It has a separate antitrust lawsuit pending alleging Mylan engaged in illegal conduct to squelch competition to EpiPen.

Mylan shares rose 2.10 percent to $31.11 on the Nasdaq.

The EpiPen, which Mylan acquired in 2007, is a handheld device that treats life-threatening allergic reactions by automatically injecting a dose of epinephrine.

Mylan came under fire last year after raising the price of a pair of EpiPens to $600, from $100 in 2008, enraging consumers and putting it in the center of the ongoing U.S. debate over the high cost of prescription medicines.

Mylan has since offered its own generic version for about $300. The company announced it had reached a Justice Department settlement in October.

Some congressional members previously criticized the $465-million settlement as too small. U.S. Senator Richard Blumenthal, a Democrat from Connecticut, renewed that position on Thursday, calling it "completely insufficient."

A U.S. Department of Health and Human Services' Office of Inspector General analysis released in May found the U.S. government may have overpaid for EpiPens by up to $1.27 billion between 2006 and 2016.

"Absolving Mylan from a finding of wrongdoing has cleared the way for the company to pocket the money it embezzled from an American public in desperate need of lifesaving and affordable medications," Blumenthal said in a statement.

Republican Senator Chuck Grassley of Iowa in a statement called the accord a "disappointment," saying it "looks like the settlement amount short-changes the taxpayers."

Mylan shares were up 0.1 at $30.50 in late trading.

  1. What legal issues do you see that relate to this article? Did the company adhere to legal requirements before and during the event? What exposure to its shareholders did the company's behavior create?

Step by Step Solution

There are 3 Steps involved in it

Step: 1

blur-text-image

Get Instant Access to Expert-Tailored Solutions

See step-by-step solutions with expert insights and AI powered tools for academic success

Step: 2

blur-text-image_2

Step: 3

blur-text-image_3

Ace Your Homework with AI

Get the answers you need in no time with our AI-driven, step-by-step assistance

Get Started

Recommended Textbook for

Problems In Contract Law Cases And Materials

Authors: Charles L. Knapp, Nathan M. Crystal, Harry G. Prince

9th Edition

1543801471, 978-1543801477

More Books

Students also viewed these Law questions

Question

dx dt = -23 sinf 529 cost sing 12 T - 529 cos +1071

Answered: 1 week ago